Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 705

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 705
---
 | D-48 |
| Exhibit B Form of Pre-Funded Warrant            |     | D-49 |
| Exhibit C Form of Registration Rights Agreement |     | D-50 |
| Exhibit D Jefferies Required Disclosure         |     | D-51 |
| Exhibit E Form of Lock-Up Agreement             |     | E-52 |

D-iii

THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of
December 19, 2024, by and among Aadi Bioscience, Inc., a Delaware corporation (the “Company”), and the persons listed on attached to this Agreement (each, a “Purchaser” and together, the
“Purchasers”).

WHEREAS, the Company desires to issue and sell to the Purchasers, and each Purchaser desires to purchase
from the Company, severally and not jointly, upon the terms and subject to the conditions stated in this Agreement, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and/or pre-funded warrants to purchase Common Stock in the form attached hereto as (the “Pre-FundedWarrants”);

WHEREAS, concurrently with the execution of this Agreement, the Company has entered into an Intellectual Property License Agreement with WuXi
Biologics (Shanghai FX) Co., Ltd., a corporation organized and existing under the laws of China (“WuXi Biologics,” and such license agreement, the “License Agreement”), pursuant to which the Company desires to
obtain an exclusive license to certain patents, know-how and other intellectual property controlled by WuXi Biologics relating to certain pre-clinical stage development
programs focused on antibody drug conjugates;

WHEREAS, the proceeds from the sale of the Shares (as defined below) and the Pre-Funded Warrants are anticipated to be used, in part, to fund certain upfront payments due to WuXi Biologics under the License Agreement;

WHEREAS, stockholder approval, at a meeting of stockholders of the Company, of the issuance of the Securities (as defined below) pursuant to
this Agreement is required in accordance with Nasdaq Listing Rule 5635(a) and, as applicable, (b) and/or (d) (as defined below) (such approval, the “Required Stockholder Approval”);

WHEREAS, the Closing (as defined below) is contingent upon, among other things, the Company’s receipt of the Required Stockholder
Approval;

WHEREAS